It was a mixed day for Daewoong Pharmaceutical Co. Ltd., which disclosed separately on March 28 both the termination of a ...

Researchers from the University of Queensland recently provided details on the discovery and preclinical characterization of ...

Digital therapeutics coupled with drugs has the potential to transform health care and change the way patients are treated, ...

Australia’s top universities are looking more to Asia for research collaborations following threats from the Trump ...

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies activating the immune system to kill tumor cells, representing ...

The first disease modifying therapies for Alzheimer’s may have limited utility in some senses, but they will be a force for ...

Scientists at Zhengzhou University and affiliated organizations synthesized and optimized a series of thienopyridine indole derivatives leading to the identification of compound [I] as the lead ...

BioWorld recorded 148 updates from phase I to phase III trials, marking a decline from the 171 updates tracked in January.

A variant burden analysis for bipolar disorder was performed using gene-based aggregation of loss-of-function variants in whole-genome sequencing data from Iceland and the UK Biobank; the association ...

In a move that undoubtedly has the unspoken support of the medical device industry, the U.S. Environmental Protection Agency (EPA) reported it will revisit several rules governing emissions that ...

Milestone Pharmaceuticals Inc.’s heart rhythm-restoring calcium channel blocker for paroxysmal supraventricular tachycardia (PSVT) has yet another obstacle in its way.

Kymera Therapeutics Inc. has described proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a signal transducer and activator of ...